Rating Change
Cantor Fitzgerald analysts initiated coverage on Ensysce Biosciences, Inc. (NASDAQ:ENSC) with a rating of Overweight on October 20, 2026.
new coverageNASDAQ:ENSC
Cantor Fitzgerald Initiates Coverage on Ensysce Biosciences, Inc. (ENSC) with Overweight
Cantor Fitzgerald analysts initiated coverage on Ensysce Biosciences, Inc. (NASDAQ:ENSC) with a rating of Overweight on October 20, 2026.
At publication ·
What changed
Ensysce Biosciences, Inc. (NASDAQ:ENSC) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $0.50
- Market capitalization
- $3.4M
At a glance
Key takeaways
- Cantor Fitzgerald initiated Overweight coverage on Ensysce Biosciences on October 20, 2026, with all 5 most recent analyst ratings being Buy or Overweight.
Market Context
Ensysce Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $0.50 with a market capitalization of $3.4M. The stock has declined 80.4% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ensysce Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ensysce Biosciences, Inc.
Among the 5 most recent ratings: 5 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 25, 2023 | HC Wainwright & Co. | Buy | N/A |
| Jul 03, 2023 | HC Wainwright & Co. | Buy | N/A |
| Nov 17, 2022 | Lake Street | Buy | N/A |
| Nov 30, 2021 | Lake Street | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ENSC Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ENSC?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Ensysce Biosciences, Inc. (NASDAQ:ENSC). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ENSC forecast page.